No. 6,150,163 (Genzyme) outlines chondrocyte media for mulations and culture procedures, in which dedifferentiated human articular chondrocytes are grown in a medium con taining TGFB and either insulin or insulin-like growth factor.
0006 Jorgensen et al. (Ann. Rheum. Dis. 60:305, 2001) reviews recent progreSS in Stem cells for repair of cartilage and bone in arthritis. Jakob et al. (J. Cell. Biochem. 26:81, 2001 ) studied specific growth factors involved in expansion and redifferentiation of adult human articular chondrocytes that enhance chondrogenesis and cartilage formation. M.
Brittberg (Clin. Orthop. 367 Suppl:S147, 1999) reviews current chondrocyte transplantation procedures in which pure chondrocytes or other mesenchymal cells are harvested autologously or as allografts from a healthy tissue Source, expanded in vitro, and then implanted into the defect at high density. 0007. Despite the initial success of these clinical meth ods, it is clear that current Sources of chondrocytes are inadequate to treat most of the instances of cartilage degen eration that present themselves at the clinic.
0008 Kramer et al. (Mech. Dev. 92:193, 2000 (Gardner et al., Fertil. Steril. 69:84, 1998 0056. When derived from an established line of pPS cells, the cell populations and isolated cells of this invention will have the Same genome as the line from which they are derived. This means that over and above any karyotype abnormalities, the chromosomal DNA will be over 90% identical between the pPS cells and the chondrocytes, which can be inferred if the chondrocytes are obtained from the undifferentiated line through the course of normal mitotic division. Chondrocytes that have been treated by recombi nant methods to introduce a transgene or knock out an endogenous gene are still considered to have the same genome as the line from which they are derived, since all non-manipulated genetic elements are preserved. 0057) 0.058 It is a hypothesis of this invention that an efficient way to perform the derivation of chondrocytes from pPS cells is to initiate differentiation of the pPS cells in a non-specific manner, and then combine the initiated cells with chondrocyte-specific differentiation factors.
Initiating the Differentiation Process 0059) One alternative is to cause the pPS cells to form embryoid bodies or aggregates: for example, by Overgrowth of a donor pPS cell culture, or by culturing pPS cells in Suspension in culture vessels having a Substrate with low adhesion properties that allows embryoid bodies to form. In an exemplary method, confluent monolayer cultures of hES cells are harvested by incubating in 1 mg/mL collagenase for 5-20 min, and dissociated into clusters. They are then plated in non-adherent cell culture plates (CoStar) in a medium composed of 80% knockout DMEM (Gibco) and 20% non-heat-inactivated fetal bovine Serum (Hyclone), Supple mented with 1% non-essential amino acids, 1 mM glutamine, 0.1 mM f-mercaptoethanol. The embryoid bod ies are fed every other day by the addition of 2 mL of medium per well. 0060. As an alternative, the differentiation process can also be initiated by culturing in a non-Specific differentiation paradigm: for example, by including retinoic acid (RA) or dimethylsulfoxide (DMSO) in the culture medium. Another method to initiate differentiation by plating the undifferen tiated pPS cells onto a substrate that stimulates the differ entiation process, Such as polyornithine. See International patent publication WO 01/51616. 0061 Driving Differentiation Towards Chondrocytes 0.062. In order to direct the culture towards the chondro cyte pathway, pPS cells that have been initiated as described in the last Section are cultured in a cocktail of chondrocyte differentiation factors. Alone or in combination, each of the factors may direct cells to differentiate down the chondro cyte pathway, cause outgrowth of cells with a chondrocyte phenotype, inhibit growth of other cell types, or enrich for chondrocytes in another fashion: it is not necessary to understand the mechanism resulting in chondrocytes being enriched in order to practice the invention. 0.063 Candidate components of the chondrocyte differ entiation mix include transforming growth factors (espe Jun. 12, 2003 cially TGFB1, TGFB2 and TGFB3), fibroblast growth factors (especially basic fibroblast growth factor, FGF-2), growth and differentiation factors (especially GDF-5, GDF-6 and GDF-7), bone morphogenic proteins (especially BMP-2, BMP-4, BMP-5, BMP-6 and BMP-7), hedgehog proteins (especially Indian hedgehog, IHH), L-ascorbic acid, and parathyroid hormone-related protein (PTHrP). Gibco is a preferred source of basic FGF. Most of the other compounds are available from R&D Systems, Minneapolis Minn. 0064. It is a hypothesis of this invention that the profile of Signaling factors and their receptors change as differen tiation proceeds, and the resultant cell populations are also changing with time. To Screen potential chondrocyte differ entiation factors, pPS cells can be cultured as aggregate bodies for various times from 0 to 10 days, to capture a broad range of differentiation Stages for the Second Step of the protocol. At each of the time points, the initiated aggre gates are disaggregated and replated in a medium containing a mixture of candidate factors.
It is also a hypothesis of this invention that differ entiation of pPS cells into chondrocytes is enhanced if cells are kept in clusters.
Interaction between cells in the clusters may be important to keep the cells from dedifferentiating, and routed along the pathway to the desired phenotype. 0066 Accordingly, the aggregate cells are gently sepa rated using a limiting amount of protease Such as trypsin, or by mechanical trituration. They are then replated in high density cultures known as micromass cultures. Briefly, the cell clumps are suspended at about 6x10" cells/mL in a medium containing ~10% serum, and plated at 50 u/well (filling the bottom 4" of each well) in a 96-well plate, precoated with a Suitable matrix Such as gelatin. After 2 hours, the cells will adhere to one another, forming cell plugs. At this point, an additional 200 till of medium is added, and the cells are cultured, changing medium daily if necessary because of the high density. The chondrocytes Synthesize abundant matrix that cements the cell clusters together. 0067. The cell clusters are then cultured with the mixture of differentiation factors for a period Sufficient to cause Selection or outgrowth of the desired phenotype (perhaps 1 or 2 weeks). As a pilot study, factors are Studied in functional groups-for example, mixtures of TGFBs, GDFs, and BMPs are made, and tested for their ability to drive chondrocyte differentiation in various combinations with other groups, IHH, PTHrP, bFGF, and ascorbic acid. Concentration ranges for initial testing are 10-100 ng/mL for BMPs, GDFs, and TGFBs; 10-100 nM for PTHrP, and 0.1 to 1 mM for IHH. After analysis of the cells according to their phenotypic markers, as described in the next Section, the groups unnec essary for differentiation are eliminated, and the important groups are dissected into their individual components. After Several iterations, a minimal component mixture is deter mined, containing a particular factor or a cocktail of 2, 3, or more factors that generates the desired phenotype. 0068. Other ligands or antibodies that bind the same receptors can be considered equivalents to any of the recep tor ligands referred to in this disclosure. for flow cytometry analysis is provided in Gallacher et al., Blood 96:1740 , 2000 . Expression of a cell-surface antigen is defined as positive if a Significantly detectable amount of antibody will bind to the antigen in a Standard immunocy tochemistry or flow cytometry assay, optionally after fixa tion of the cells, and optionally using a labeled Secondary antibody or other conjugate to amplify labeling. Possible Sources of Specific antibody are shown in Table 1 . Sequence data for particular markers listed in this disclosure can be obtained from public databaseS Such as GenBank. 0078. To facilitate engraftment, it is beneficial to maxi mize the proportion of cells in the population that have the characteristics of chondrocytes or their precursors, by refin ing the mixture of differentiation factors, culture conditions, and timing and following these markers. Populations in which at least 5% of the cells synthesize either Type II collagen or aggrecan, or both, may well be workable if the other cells in the population are inert, or play other roles in connective tissue (Such as fibroblasts or mesenchymal cells).
Populations enriched to the point where at least 25% of the cells Synthesize either Type II collagen or aggrecan would be more efficacious in a number of contexts.
0079 For therapeutic applications relating to cartilage regeneration, it is usually desirable to minimize the ability of the cell population to form elastic cartilage, fibrocartilage, hypertrophic cartilage and bone. This means that the pro portion of cells Synthesizing Type I collagen, Type X col lagen, or osteocalcin (alone or in combination) is as low as possible, preferably below /s" of the cells staining positive for Type II collagen or aggrecan, or less than 1%. Also desirable are populations with a low residual proportion of undifferentiated pPS cells. Preferred populations are less than 1%, or 0.2% SSEA-4 +ve, Oct-4 +ve, or positive for expression of endogenous telomerase reverse transcriptase. 0080 Animal Model Experiments 0081. Of considerable interest for development of chon drocytes for clinical application is the ability of cell popu lations to model cartilage and restore joint function in a host. Reconstitution of chondrocyte function can be tested using several well-established animal models.
0082 Pilot experiments can be conducted using a model in which 6 mm holes are put in the external ear of the rabbit, leaving the adherent skin intact. MatrixeS. Seeded with chon drocytes are then implanted, and the animals are monitored for hole closure (ten Koppel et al., Biomaterials 22:1407 , 2001 ).
0.083 Alternatively, full thickness defects can be created in the weight bearing Surface of the medial femoral chondyle of femora in rabbits (Grigolo et al., Biomaterials 22:2417 , 2001 ). The wounds are repaired using chondrocytes Seeded on a biomaterial, or pulled as a multicellular aggregate from the micromass culture. A membrane Such as a piece of the periosteum or facia may be used to fold the implant in place, or matrix implants can be held in place with Surgical dart. The full-thickness defect allows blood to seep into the site from the marrow cavity, creating a clot that contains endog enous Stem cells. Rather than the medial chondyle, the work can be done with a defect created in the trochlear groove. This is a non-weight-bearing Site, and implants are not dislodged as easily as from the medial chondyle. 0084. Histologic samples from the treatment site are examined 1-6 months after Surgery for population with the implant cells and cartilage deposits. This includes immun Ostaining for Type II collagen and aggrecan. Important morphological characteristics of the implant include carti lage thickness, Smooth articular Surface, and integration of the implant and endogenous cartilage at the borders of the defect. Long-term Stability of the implant can be verified at the 12 month point. 0085. As another option, a partial thickness defect can be created that doesn't penetrate the underlying bone or mar row cavity (Hunziker et al., Clin. Orthop. 391 Supp:S171, 2001 ). This type of defect serves as a model for osteoar thritis. Another model for osteoarthritis involves injection of estradiol into the knee joint of Ovarectomized rabbits, caus ing loss of condyle Surface congruity that resemble the defects observed in osteoarthritis in humans (Tsai et al., Clin Orthoop. 291:295, 1993 12. A pharmaceutical composition for producing, repair ing, or maintaining cartilage in Vivo, comprising the cell population of claim 1 in a physiologically compatible excipient.
13. The pharmaceutical composition of claim 12, further comprising a matrix that is reabsorbed in Vivo.
14. A method of Screening a compound for its ability to modulate chondrocyte growth, differentiation, or Synthesis of cartilage components, comprising combining the com pound with the cell population of claim 1, determining any phenotypic or metabolic changes in the cell population that result from being combined with the compound, and corre lating the change with an ability of the compound to modulate chondrocyte growth, differentiation, or Synthesis of cartilage components.
15. A method of reconstructing cartilage in a Subject, comprising administering to the Subject the cell population of claim 1.
